Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney trans...

ver descrição completa

Detalhes bibliográficos
Autores: Buxeda, Anna, Arias-Cabrales, Carlos, Pérez-Sáez, María José, Cacho, Judit, Cabello Pelegrin, Sheila, Melilli, Edoardo, Aladrén, María José, Galeano, Cristina, Lorenzo, Inmaculada, Mazuecos, Auxiliadora, Saura, Isabel María, Franco, Antonio, Ruiz-Fuentes, María Del Carmen, Sánchez-Cámara, Luis Alberto, Siverio, Orlando, Martin, María Luisa, González-García, Elena, López, Verónica, Martin-Moreno, Paloma Leticia, Moina, Iñigo, Moral Berrio, Esperanza, Moreso, Francesc, Portolés, José María, Santana-Estupiñán, Raquel, Zárraga, Sofía, Canal, Cristina, Sánchez-Álvarez, Emilio, Pascual, Julio, Crespo, Marta
Tipo de documento: artigo
Data de publicação:2021
País:España
Recursos:Instituto de Salud Carlos III (ISCIII)
Repositório:Repisalud
Idioma:inglês
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/18398
Acesso em linha:http://hdl.handle.net/20.500.12105/18398
Access Level:Acceso aberto
Palavra-chave:SARS-CoV-2
Acute kidney injury
Immunosuppression
Kidney transplantation
Remdesivir
Descrição
Resumo:Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.

Registros relacionados